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Genetic programs that govern neural stem/progenitor cell (NSC) proliferation and differentiation are
dependent on extracellular cues and a network of transcription factors, which can be regulated posttransla-
tionally by phosphorylation. However, little is known about the kinase-dependent pathways regulating NSC
maintenance and oligodendrocyte development. We used a conditional knockout approach to target the murine
regulatory subunit (beta) of protein kinase casein kinase 2 (CK2) in embryonic neural progenitors. Loss of
CK2 leads to defects in proliferation and differentiation of embryonic NSCs. We establish CK2 as a key
positive regulator for the development of oligodendrocyte precursor cells (OPCs), both in vivo and in vitro. We
show that CK2 directly interacts with the basic helix-loop-helix (bHLH) transcription factor Olig2, a critical
modulator of OPC development, and activates the CK2-dependent phosphorylation of its serine-threonine-rich
(STR) domain. Finally, we reveal that the CK2-targeted STR domain is required for the oligodendroglial
function of Olig2. These findings suggest that CK2 may control oligodendrogenesis, in part, by regulating the
activity of the lineage-specific transcription factor Olig2. Thus, CK2 appears to play an essential and
uncompensated role in central nervous system development.
Casein kinase 2 (CK2) is a conserved serine/threonine ki-
nase with more than 300 substrates, mostly proteins related to
transcription-directed signaling (27). CK2 is a heterotet-
rameric holoenzyme formed by two catalytic subunits,  and
, that associate with a dimeric building block of regulatory 
subunits (22). CK2 modulates the substrate specificity of
the CK2 enzymatic activity, and its architecture is consistent
with its role as a docking partner for other interacting proteins
(4). We previously demonstrated that disruption of CK2 func-
tion in mice results in postimplantation lethality. Moreover,
many attempts to generate CK2/ embryonic stem (ES)
cells failed, suggesting an essential role of mammalian CK2
for ES cell viability (2).
The function of CK2 for cell cycle progression has been
investigated, but its precise role is largely unknown. The cell
proliferation function of CK2 was first characterized in hu-
man fibroblasts, by use of antisense oligodeoxynucleotides and
microinjection of specific antibodies (19, 26). Recently, a ge-
nome-wide survey of protein kinases required for cell progres-
sion into cultured Drosophila melanogaster S2 cells by double-
stranded RNA demonstrated that CK2 is required for
centrosomal normality (1). In the same vein, downregulation
of CK2 by small interfering RNA (siRNA) results in delayed
cell cycle progression in cultured mammalian cells (42). Fi-
nally, in a genetic screen for mutations affecting the central
brain of Drosophila, a hypomorphic allele of D. melanogaster
CK2 has been isolated, and that study suggested a role for
CK2 in cell proliferation or cell survival during brain devel-
opment (15).
In the developing mouse brain, neural stem/progenitor cells
(NSCs), which reside in the ventricular zone (VZ), give rise to
neurons and glial cells (astrocytes and oligodendrocytes) (23).
Chronologically, neurons are generated first, and glial cells are
generated subsequent to neurogenesis. Oligodendrocytes orig-
inate from ventral neural progenitors in the VZ, and once
committed, they migrate laterally and dorsally as parenchymal
precursors (oligodendrocyte precursor cells [OPCs]) to popu-
late the entire embryonic telencephalon, where they terminally
differentiate (reviewed in reference 29). Distinct genetic pro-
grams using combinations of transcription factors govern mul-
tiple spatiotemporal origins of oligodendroglial specification
(reviewed in reference 28). The basic helix-loop-helix (bHLH)
transcription factor Olig2 plays an essential role in the embry-
onic specification of neural progenitors into the oligodendro-
cyte lineage, and Olig2 gene function is absolutely required for
OPC development (17, 21, 36, 43). Accordingly, Olig2 expres-
sion is detected first in ventral neural progenitors, precedes
OPC-specific expression markers, and is maintained at all
stages of oligodendrocyte development (29). It has been re-
ported that the oligodendroglial function of Olig2 can be mod-
ulated by protein kinase AKT-mediated phosphorylation of its
N-terminal domain (31). Interestingly, neural bHLH transcrip-
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tion factors have been described as being phosphorylated and
regulated by the CK2 holoenzyme (9, 39). In the mouse brain,
CK2 subunits (, , and ) are expressed in all neural cells (A.
Kolding and B. Boldyreff, unpublished data) in which the
CK2-to-CK2-plus-CK2 ratio is largely elevated compared
to that in other organs (41), suggesting a higher-threshold
requirement in the amount of the holoenzyme in the central
nervous system (CNS). All together, these observations suggest
that CK2 may modulate neural homeostasis.
In this study, we have used Cre/loxP-mediated recombina-
tion to generate mice with a CK2 null allele in NSCs of the
developing brain. Disruption of CK2 results in inhibition of
NSC proliferation and in a severe deficiency for progenitors to
specify OPCs. In addition, we identified, in vitro, the serine-
threonine-rich (STR) domain of Olig2 as a strict CK2-depen-
dent, CK2-targeted substrate. We also show that the STR
domain of Olig2 is a modulator of its oligodendroglial activity
when tested in neurosphere assays, suggesting that CK2 could
mediate its effect via Olig2 oligodendroglial activity. Hence,
these findings provide insight into the genetic basis underlying
neural progenitor proliferation and oligodendrocyte develop-
ment.
MATERIALS AND METHODS
Mouse breeding. Mice were of a C57BL/6 background. Nestin-cre transgenic mice
(37) kept as heterozygotes were bred with CK2loxP/loxP mice (2). Double-heterozy-
gous mice (CK2loxP/wt; Nestin-cre) were bred back to CK2loxP/loxP mice to produce
the genotypes used in this study, (i) CK2loxP/wt, (ii) CK2loxP/loxP, (iii) CK2loxP/wt,
Nestin-cre, and (iv) mutant CK2loxP/loxP, Nestin-cre (referred to here as CK2).
CK2loxP/wt, CK2loxP/loxP, and CK2loxP/wt, Nestin-cre embryonic day 18.5 (E18.5)
embryo phenotypes were identical and are referred to here as wild type (WT).
Live-born mice, postnatal day 0 (P0) pups, and E18.5 embryos were genotyped by
tail DNA PCR (2). Animal treatment was performed in accordance with the ethics
committee (ComEth) of Grenoble, France.
Western blot analysis. Olfactory bulb, cerebellum, and meningeal cells were
removed from dissected brains. Forebrain protein extracts were obtained after
homogenization and sonication in 25 mM Tris (pH 8.5)–1 mM dithiothreitol
(DTT)–200 mM NaCl–5 mM EDTA. Cells were lysed in 50 mM Tris (pH 7.5)–5
mM EDTA–500 mM NaCl–1% Triton X-100. Extractions were done with pro-
tease and phosphatase inhibitor cocktails (Sigma). Samples (40 g) were ana-
lyzed by 12% SDS-PAGE and processed for Western blot analysis. Antibodies
used were rabbit anti-CK2 (1/500, directed against the C terminus of CK2),
rabbit anti-CK2 (1/1,000; Calbiochem), mouse anti--tubulin class III isoform
(1/1,000; Chemicon), rabbit anti-poly(ADP-ribose) polymerase (anti-PARP) an-
tibody (1/1,000; Cell Signaling), and mouse antihemagglutinin (anti-HA) anti-
body (clone 12CA5, 1/1,000; Roche).
Histological, immunochemical, and in situ hybridization analyses. Embryos
were perfused intracardially with 4% paraformaldehyde (PFA). Dissected brains
were postfixed overnight at 4°C and processed for paraffin or OCT embedding.
Paraffin samples were cut at 5 m and used for hematoxylin and eosin (H&E) or
for immunochemical analysis. In order to detect proliferating cells in S phase
(bromodeoxyuridine [BrdU] labeling), a 1-h short pulse was performed as de-
scribed previously (2). Paraffin-embedded sections were incubated with an anti-
BrdU rat monoclonal antibody (1/75; Harlan, Indianapolis, IN). Mitotic cell
activities were detected with a rabbit antibody, anti-Ser10 phospho-H3 (PH3,
1/2,000; Upstate). Frozen sections (16 m) were used for immunostaining. Cryo-
sections were incubated in a blocking solution (phosphate-buffered saline [PBS]–
0.2% Triton X-100–5% normal goat serum) for 20 min and with a mouse IgG
blocking reagent (Vector) for 1 h. The primary antibodies used were mouse
anti-RC2 (1/10; Hybridoma Bank, University of Iowa), rat anti-GFAP (1/500;
U.S. Biological), rabbit anti-NG2 antibody (1/100; Chemicon), rat anti-PECAM
antibody (1/2; gift from A. Vecchi, Milan, Italy), rabbit anti-Olig2 antibody
(1/20,000; gift from C. Stiles, Boston, MA), and mouse anti-Ki67 (clone MM1,
1/100; Novocastra). Primary antibodies were diluted in PBS–1% normal goat
serum, followed by appropriate cyanin-3 dye-conjugated, cyanin-2 dye-conju-
gated (1/500; Jackson ImmunoResearch Laboratories), Alexa488 dye-conjugated
(1/500; Molecular Probe), or horseradish peroxidase (HRP) 3,3-diamino-
benzidine staining system secondary antibodies. Cells were stained with Hoechst
dye 33342 (2 g/ml) to visualize nuclei. Images were acquired using a Zeiss
fluorescent microscope (Axiovert 200 M) with 16 and 40 objectives. Images
were combined for figures by using Adobe Photoshop 8.0. In situ hybridization
using antisense, digoxigenin-labeled Pdgfra riboprobe was performed as de-
scribed previously (20).
Neurosphere culture. E18.5 forebrains from diverse CK2 genetic back-
grounds were subjected to trypsin digestion for 15 min at 37°C. Tissues were
mechanically dissociated into single-cell suspensions, filtered through a 70-m
cell strainer, and further treated with 10 g DNase I (Roche) for 10 min at room
temperature. Cells from individual embryos, 2  106 cells/10-cm-diameter un-
coated dish, were cultured for primary neurosphere assays in Dulbecco’s modi-
fied Eagle’s medium (DMEM)-F12 medium with B27 complement (D/F-B27)
containing 10 ng/ml epidermal growth factor (EGF; PeproTech) and 10 ng/ml
fibroblast growth factor-2 (FGF; gift from G. Bouche, Toulouse, France). Num-
bers of generated primary spheres were counted after 4 days of in vitro culture
(4DIV). To assess for proliferation, 7DIV primary spheres were mechanically
dissociated and individual viable cells were counted. These cells (6  105 cells/
10-cm-diameter uncoated dish) were also used to assess for self-renewal in
secondary neurosphere assays. Olig neurospheres were generated from neural
stem/progenitor cells (NSCs) isolated from ganglionic eminences of Olig2/ or
Olig2/ E14.5 embryos (18). For rescue experiments, Olig2/ NSCs were
subsequently infected with HA-tagged Olig2-encoding viruses (see below) and
selected with blasticidin (2 g/ml) 48 h after infection. Expression of HA-Olig2
proteins was confirmed by immunocytochemistry. For NSC differentiation assays,
4DIV neurosphere cultures were plated on poly-L-lysine-coated glass coverslips
(at a density of 50 neurospheres/cm2) and shifted into D/F-B27 medium in the
presence of 3.5% fetal bovine serum (FBS; Biowest) (differentiating medium)
(11). 3DIV after plating, differentiated cultures were fixed with the PFA solution
and processed for immunocytochemistry. Additional primary antibodies were
mouse anti--tubulin III (1/500; Babco), mouse anti-O4 (1/10; gift from C. Soula,
Toulouse, France), rat anti-Pdgf receptor a chain (1/100; BD PharMingen), and
rat anti-HA (clone 3F10, 1/500; Roche).
Embryonic stem cell culture. CK2loxP/wt and CK2loxP/ ES cell lines cul-
tured in the presence of 103 units/ml leukemia inhibitory factor (LIF; Chemicon)
and Cre–pMSCV-puro viral supernatant have been described previously (2). The
PCR product corresponding to HA-tagged CK2wt coding regions was amplified
using oligonucleotide DNA primers (5 primer A [5-CGGAATTCGCCGCCA
CCATGTATCCTTATGATGTTCCTGATTATGCTATGAGCAGCTCCGAG
GAGGTG-3] and 3 primer B [5-GAAGATCTTCAGCGGATGGTCTTCAC
G-3]) and cloned into EcoRI/BglII pMSCV-neo viral vector sites (Clontech).
CK2 viral supernatants were generated by transfection of BOSC23 cells. Viral
HA–CK2–pMSCV-neo supernatants were first used to infect 2.5  104/cm2
CK2loxP/ ES cells. To avoid chimera colonies, one day after infection, ES cells
were subjected to trypsin treatment and individual cells were plated. Neomycin
(Neo) selection (350 g/ml) was started 48 h after infection, and Neor clones
were expanded and screened for expression of exogenous the HA-CK2wt pro-
tein by Western blot analysis using mouse anti-HA antibody. Selected Neor
clones were further infected with Cre–pMSCV-puro supernatant. (CK2loxP/wt
ES cells were used as positive controls.) One day later, individualized ES cells
were plated, and puromycin (puro) selection (1.5 g/ml) was started 48 h postin-
fection for 6DIV or 9DIV. Individual clones were expanded and analyzed by
PCR analysis and Southern blot analysis for the absence of the CK2loxP allele
(2) and by Western blot analysis for the absence of the endogenous wild-type
CK2 protein. Neor puro-resistant CK2/ ES cells expressing only the exog-
enous HA-CK2wt protein were seeded in the absence of LIF (3  106 cells/10-
cm-diameter uncoated plate/10 ml) to form floating embryoid bodies (EBs). In
order to stimulate neural differentiation, 5 M retinoic acid was added after
4DIV of EB cultures and left for additional 4 days. EBs were further dissociated
with trypsin, and individual cells (3 106 cells/10-cm-diameter uncoated plate/10
ml) were used in neurosphere assays.
CK2 activity. Crude embryonic E18.5 forebrain extracts (adjusted to 5 mg/ml
of protein concentration) were assayed for CK2-dependent CK2 kinase activity
at 22°C for 10 min using a 3 mM concentration of the CK2-specific synthetic
peptide RRREEETEEE (13) and [	-32P]ATP. One unit of CK2 activity is
defined as the amount of activity necessary to transfer 1 fmol of phosphate per
minute into the synthetic peptide. Chromatographic fractions (5 l) were assayed
for 3 min with a 150 M concentration of the CK2 consensus synthetic peptide
RRREDEESDDEE (32) or with a purified fusion protein fragment consisting of
glutathione S-transferase (GST) and Olig2 amino acids 1 to 177 [Olig2(1-177)].
The PCR product corresponding to the mouse Olig2(1-177) coding region was
amplified from the Olig2 CMV2 template (34) by using the Expand high-fidelity
PCR system (Roche) with oligonucleotide DNA primers (5 primer C [5-TTG
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AATTCATATGGACTCGGACGCCAGCCT-3] and 3 primer D [5-AACTC
GAGTCAGTAGATCTCGCTCACCAGTC-3]) and subcloned into EcoRI/
XhoI pGEX4T2 vector sites (Amersham Biosciences) in order to generate the
GST-Olig2(1-177) fusion protein. Purified GST-Olig2 proteins (20 g) were
incubated at 22°C for 0 to 30 min with 25 M [	-32P]ATP and 12 mM MgCl2 in
the presence of 60 to 240 ng of CK2 subunit with increasing amounts of
equivalent CK2 subunit (0 to 230 ng). Phosphorylated proteins were analyzed
by SDS electrophoresis and autoradiography.
Phosphopeptide mapping and automated Edman degradation. The phosphor-
ylated GST-Olig2(1-177) fusion protein was excised from the nitrocellulose
membrane and digested in situ with trypsin (modified sequencing grade; Pro-
mega). Two-dimensional phosphopeptide mapping was done using thin-layer
electrophoresis (HTLE-7000; CBS Scientific). First-dimension electrophoresis
was performed in pH 1.9 buffer (formic acid, glacial acetic acid, and water at
50:156:1,794, vol/vol/vol) for 30 min at 2,000 V, and chromatography in the
second dimension was performed in isobutyric acid–n-butyl alcohol–pyridine–
glacial acetic acid–water (1,250:38:96:58:558, vol/vol/vol/vol/vol). After exposure,
phosphopeptides were eluted from the plates in pH 1.9 buffer and lyophilized;
aliquots of the samples were coupled to Sequelon-AA membrane (Millipore
Corp.) by use of carbodiimide coupling and subjected to automated Edman
degradation by using an Applied Biosystems sequencer (model 477A). Released
phenylthiohydantoin derivates from each cycle were spotted onto thin-layer
chromatography plates. The radioactivity in each spot was revealed by exposure
on a FujiX Bio-imager.
GST pull-down assay. Additional PCR products corresponding to coding
regions for mouse Olig2 N-terminal amino acids 1 to 108 [N-ter(1-108)] and
Olig2 bHLH amino acids 109 to 177 [bHLH(109-177)] were additionally ampli-
FIG. 1. CK2 loss in the central nervous system impairs telencephalon development. (A) Western blot analysis of CK2 and CK2 expressions
in E16.5 and E18.5 forebrain extracts. A specific neuronal (class III -tubulin [ III Tub]) antibody was used to control protein normalization.
(B) CK2-dependent CK2 activity in E18.5 CK2loxP/loxP, Nestin-cre forebrain extracts was significantly reduced (***, P 
 2.7  10
9 [3 extracts
in quadruplicate per genotype]) compared to that in wild-type controls. (C) Brain morphology of E18.5 CK2loxP/loxP, Nestin-cre embryos compared
to that of the wild type. (D) Representative H&E staining of E18.5 anterior forebrains. Black and red boxed areas are shown at higher
magnification in panel E. (E) At the level of the corpus callosum (CC; black boxes), linear arrays of cells (arrows) detected in wild-type embryos
were absent in the mutants. In contrast, laminar patterns appeared similar in the cortex (Ctx; red boxes). MZ, mantle zone; CP, cortical plate zone;
SP, subplate zone. Scale bars, 1 mm (C and D) and 100 m (E).
TABLE 1. Genotypes of live-born mice and embryos from














Live-born mice 22 18 15 0
P0 3 5 4 5
E14.5/E16.5/E18.5 142 146 148 154
a For details, see Materials and Methods.
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fied and subcloned into the pGEX4T2 vector as described above using 5 primer
C with 3 primer E (5-AACTCGAGTCACTGCTGCAGCTCGGGCTCAG-3)
and using 5 primer F 5-TTGAATTCATATGCTGCGCCTGAAGATCAACA
GCCGCGA-3 with 3 primer D, respectively. Interaction assays were performed
using prebound GST or GST-Olig2 glutathione Sepharose beads (Amersham
Biosciences) equilibrated in PBS–0.05% Tween 20–1 mg/ml bovine serum albu-
min (BSA) and incubated in the presence of [35S]methionine-labeled CK2 (2 
105 cpm) at 22°C for 90 min. Bound CK2 subunits were analyzed by SDS
electrophoresis and autoradiography.
Construction of HA-tagged mouse Olig2 vectors. A PCR product correspond-
ing to the HA-tagged mouse Olig2(1-177) coding region was amplified using 5
primer G (5-TTGAATTCTGGGCCATGTACCCATACGATGTTCCAGATT
ACGCTATGGACTCGGACGCCAGCCT-3) and 3 primer H (5-GAAGAT
CTCGCTCACCAGTCGCT-3) and subcloned into EcoRI/BglII sites of the
Olig2 CMV2 vector (34) to generate HA-tagged full-length mouse Olig2wt(1-
323). The CMV2 vector with HA-Olig2 STR amino acids 77 to 94 (STR77-94)
deleted (HA-Olig2STR) was generated by site directed mutagenesis using sense
primer I (5-TGGGCGGCGGTGGCTTCAAGAAGAAAGACAAGAAGCAG
AT-3) and antisense primer J (5-ATCTGCTTCTTGTCTTTCTTCTTGAAG
CCACCGCCGCCCA-3). Construction of pWZL-BLAST viral vectors encod-
ing HA-Olig2wt and HA-Olig2STR proteins were generated after subcloning
EcoRI/XhoI PCR fragments obtained after amplification with respective CMV2
templates by using a GC-rich DNA polymerase (Invitrogen) with 5 primer G
and 3 primer K (5-AACTCGAGTCACTTGGCGTCGGAGGTGAG-3).
Cos7 cell transfection and coimmunoprecipitation assay. For coimmunopre-
cipitations, a Flag-tagged CK2 construct was produced after PCR amplification
using 5 primer L (5-TTGGATCCGCCGCCACCATGGACTACAAGGACG
ACGACGACAAGATGAGCAGCTCCGAGG-3) and 3 primer M (5-GAAG
ATCTTCAGCGGATGGTCTTCACG-3) and cloned into BamHI/BglII pSG5
vector sites. The Flag-CK2 PSG5 and the HA-tagged full-length mouse
Olig2wt(1-323) CMV2 constructs were transiently Lipofectamine-transfected
into Cos7 cells cultured in DMEM–10% fetal calf serum (FCS). Transfected cells
were lysed in radioimmunoprecipitation assay (RIPA) buffer (48 h posttransfec-
tion) in the presence of protease inhibitors, and for each extract, protein expres-
sion levels were analyzed by Western blot analysis. Five micrograms of a mono-
clonal antibody against the Flag epitope (Sigma) were added in precleared
lysates for 1 h at 4°C. Next, 50 l of RIPA-equilibrated “mouse true blot” beads
(eBioscience) was added and incubated under constant rotation for 1 h. After the
beads were washed with RIPA buffer, the precipitated proteins were analyzed by
SDS electrophoresis and Western blotting.
Statistical measures. For kinase activities, three forebrain-derived extracts per
genotype were tested in quadruplicate. For telencephalon cell counts, at least
three embryos per genotype were used for each day postcoitum (dpc) indicated.
Cells were counted on three or more nonadjacent sections per telencephalon.
For in vitro CK2 neurosphere assays, sphere and cell counts were performed
from three or six embryo-derived cultures per genotype. For in vitro neurosphere
differentiation assays, cell counts were performed from four or more embryo-
derived cultures per genotype with six glass coverslips per culture (50 neuro-
spheres per coverslip). To evaluate the proliferation rate of neural stem cell-
derived embryonic stem cells, cell counts were performed from seven
differentiation cultures. Data are presented as averages  standard errors. Sta-
tistical comparisons were established using Student’s t test.
RESULTS
CK2 ablation in the central nervous system causes telen-
cephalon defects during late development. To gain insight into
functions of CK2 in the developing central nervous system
(CNS), we ablated CK2 in embryonic neural stem/progenitor
cells (NSCs), since loss of CK2 is lethal to mouse embryos (2).
We crossed CK2loxP/loxP mice with hemizygous Nestin-cre trans-
genic mice (37) to generate conditional mutant CK2loxP/loxP,
FIG. 2. CK2 positively controls forebrain NSC proliferation but
did not interfere with NSC specification. (A) Analysis of RC2 (red)
and GFAP (green) expressions by immunohistochemistry (IHC) in
E18.5 wild-type and CK2loxP/loxP, Nestin-cre telencephalons. Cell nu-
clei were stained with Hoechst dye 33342 (blue). (B) There was a
significant reduction (***, P 
 2.7  10
12 [3 embryos per genotype
and 3 nonadjacent sections per ventricular zone {VZ}]) of BrdU
S-phase NSCs in CK2loxP/loxP, Nestin-cre VZs (outlined with a dotted
line) of lateral ventricles compared to the number in wild-type con-
trols, as well as a near absence of PH3-positive mitotic cells.
(C) Caspase-3-dependent apoptosis analysis in E18.5 forebrains. West-
ern blot analysis of cleaved PARP in E18.5 forebrain extracts. The
control represents the staurosporine-treated (1 M, 3 h) NIH 3T3
positive extract; cleaved PARP (arrow) serves as a marker of cells
undergoing caspase-3-dependent apoptosis. Scale bars, 100 m (A)
and 50 m (B).
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Nestin-cremice (referred to here asCK2).CK2 mutant pups
were born with a Mendelian ratio (Table 1) but did not feed and
died shortly after birth. Therefore, the phenotype of embryos was
analyzed. As expected, the CK2 protein was absent in CK2
mutant E18.5 forebrain extracts (Fig. 1A). However, the CK2
protein was still detected in CK2 mutant E16.5 extracts, al-
though Cre-mediated recombination occurs at E9.5 to E10.5 (10).
This observation is in agreement with the stability of the CK2
protein integrated in the structure of tetrameric CK2 holoen-
zymes (22) and could explain the late CK2 mutant phenotype.
Importantly, the expression of the CK2 catalytic subunit was
unchanged upon CK2 ablation. We also measured the CK2-
dependent CK2 activity in E18.5 forebrain extracts by using phos-
phorylation of the CK2-specific synthetic peptide RRREE
ETEE (13). In line with ablation of CK2 in CK2 mutant
forebrains, CK2-dependent CK2 activity was significantly re-
duced (60%) in CK2 mutant extracts compared to wild-type
controls (Fig. 1B). The remaining activity in mutant extracts could
be related to holoenzyme molecules derived from blood vessel
cells present in dissected forebrains, in which Cre recombinase is
not active (10). We conclude that expression of CK2 and, thus,
the activity of CK2-dependent phosphorylation are effectively
impaired in CK2 E18.5 forebrains.
To investigate the effects of loss of the CK2 regulatory
subunit on the development of the central nervous system,
we analyzed the morphologies of E18.5 mutant brains.
Gross morphologies of wild-type and CK2 E18.5 brains
appeared similar (Fig. 1C). However, further histological
analyses showed defects in CK2 telencephalons: an ab-
sence at the corpus callosum (CC) level of cells that formed
linear, pearls-on-a-string arrays characteristic of oligoden-
droglial cells (Fig. 1E) (33) and an absence of the emerging
hippocampal dentate gyrus (data not shown). In contrast,
laminar patterns and cellular density were not affected in
the cortex (Ctx; Fig. 1D and E), suggesting that cortical
neurogenesis occurred normally in CK2 mutants. Thus,
CK2 loss in embryonic NSCs leads to morphology defects
during late development of the brain.
FIG. 3. Defective OPC development in CK2loxP/loxP, Nestin-cre telencephalons. (A) Schematic of a coronal telencephalon section. The green
and red boxes indicate the regions analyzed for the detection of parenchymal OPCs in panel B and of ventral OPCs in panel C, respectively.
(B) Analysis of NG2 (green) and PECAM (red) expressions by immunohistochemistry (IHC) in E18.5 wild-type and CK2loxP/loxP, Nestin-cre
telencephalons. Note the normal appearance of multiprocessed NG2 parenchymal OPCs in the wild type and their absence in CK2loxP/loxP,
Nestin-cre embryos. The pattern of NG2 staining in vessel pericytes parallels PECAM endothelial cell labeling (yellow) and was unaffected.
(C) NG2 and PECAM expression analysis (IHC) revealed the presence of ventral NG2 OPCs (arrowheads) in CK2loxP/loxP, Nestin-cre fetal
(E14.5) and late embryonic (E16.5 to E18.5) telencephalons. (D) In situ hybridization (ISH) analysis of Pdgfra expression in fetal (E14.5) and late
embryonic (E16.5 to E18.5) telencephalons. There was a significant reduction (***, P values of 2.5  10
10 at E16.5 and 1.0  106 at E18.5 [4
embryos per dpc and per genotype and 3 nonadjacent sections per telencephalon]) of Pdgfra OPCs in CK2loxP/loxP, Nestin-cre telencephalons
compared to the number in wild-type controls. lv, lateral ventricle. Scale bars, 100 m (B and C) and 200 m (D).
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CK2 disruption compromises forebrain stem/progenitor
cell proliferation. To understand the causes of the defects
observed in mutant brains, we studied NSCs. In mice, NSCs in
the VZs of developing brains possess radial glia morphology
and express RC2. During the late embryonic (E18.5)/neonatal
(P0) transition, radial glia gives rise to adult NSCs and pro-
gressively loose RC2 expression in favor of GFAP (23). In
CK2-ablated E18.5 embryos, neither RC2 radial glia nor
GFAP NSCs were substantially altered (Fig. 2A).
Previous results indicated that during mouse embryogenesis,
FIG. 4. Olig2 progenitor analysis in fetal and late embryonic telencephalons. (A) IHC analysis of Olig2 expression in embryonic telenceph-
alons. Parenchymal Olig2 progenitors were detected in CK2loxP/loxP, Nestin-cre E14.5, E16.5, and E18.5 telencephalons. lv, lateral ventricle; vz,
ventricular zone; MGE, medial ganglionic eminence; LGE, lateral ganglionic eminence. There was a small decrease (**, P
 3.4 10
3 [4 embryos
per dpc and per genotype and 3 nonadjacent sections per telencephalon]) in parenchymal Olig2 progenitor numbers in CK2loxP/loxP, Nestin-cre
E18.5 telencephalons compared to the number in wild-type controls. (B) Proliferation analysis of parenchymal Olig2 progenitors/OPCs by double
labeling for Ki67 (red) and Olig2 (green). The ratios (percentages) of proliferating cells (Ki67) coexpressing Olig2 in the parenchyma (yellow and
arrowheads) to total parenchymal Olig2 cells were not different between CK2loxP/loxP, Nestin-cre and wild-type E16.5 and E18.5 telencephalons
(3 embryos per dpc and per genotype and 4 nonadjacent sections per telencephalon). (C) CK2 regulates OPC specification of parenchymal Olig2
progenitors. Scale bars, 100 m (A) and 50 m (B).
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CK2 is mainly involved in proliferation rather than in the
prevention of apoptosis (2). Therefore, we examined at E18.5
the incorporation of a short pulse of BrdU in the germinal
compartment of the telencephalon, the VZ of lateral walls (lw)
of lateral ventricles (lv). CK2 VZs displayed a significant
reduction (60%) of NSCs in S phase as determined by the
extent of BrdU-labeled nuclei compared to wild-type controls
(Fig. 2B). In addition, the BrdU mutant nuclei showed a
rounded morphology instead of an elongated morphology. To
further address the effects of CK2 loss on the cell cycle,
sections were stained with the mitosis marker phospho-histone
H3. Only few CK2 NSCs were found phospho-histone H3
positive (Fig. 2B). It is possible that the reduced NSC number
represents a dysregulation of the cell cycle or an increase in cell
death. We did not detect substantial apoptosis by terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end
labeling (TUNEL) assay staining in CK2 E18.5 forebrains
(data not shown). Accordingly, cleaved PARP, a hallmark of
caspase-3-dependent apoptosis in vivo, was undetectable in
CK2 E18.5 forebrain protein extracts (Fig. 2C). Taken to-
gether, these results suggest that CK2 is important for the
proliferation, but not the genesis, of forebrain NSCs.
CK2 loss in NSCs impairs oligodendroglial differentiation
in developing telencephalons. Next, we examined whether
CK2 regulates oligodendrogenesis, as suggested by disorga-
nization of the corpus callosum of CK2 brains (Fig. 1E). We
first analyzed the expression of the oligodendroglial precursor
(OPC) marker NG2 (25) by immunohistochemistry (IHC). At
E18.5, parenchymal NG2 cells with OPC morphology were
absent in CK2 telencephalons, and only NG2 pericytes
associated with blood vessel were detected (Fig. 3B). However,
in CK2 brains, we were able to detect some NG2 OPCs in
a ventral location (Fig. 3C, E18.5 panel). In the mouse telen-
cephalon, early OPCs (E12.5 to E14.5) are of ventral origin
(reviewed in references 28 and 29). Thus, it was possible that
the remaining E18.5 ventral OPCs in CK2 brains were gen-
erated earlier during early embryogenesis, a period when the
CK2 protein is not completely ablated (Fig. 1A). Figure 3C
shows that early ventral NG2 OPCs were generated in
CK2 mutant E14.5 telencephalons, but in contrast to wild-
type controls, they did not expand during the late embryonic
period (E16.5 to E18.5). Because NG2 cytoplasmic immuno-
staining is unsuitable for quantification, we analyzed the ex-
pression of another OPC marker, Pdgfra (12, 25), by in situ
hybridization. At E14.5, the numbers of Pdgfra OPCs in wild-
type and CK2 brains were similar (Fig. 3D). However, there
was a sharp decrease (75%) in the number of Pdgfra OPCs
in E16.5 mutant telencephalons, despite incomplete inactiva-
tion of the CK2 protein. By E18.5, this difference was more
pronounced (90%).
We also investigated the expression of Olig2, a basic helix-
loop-helix (bHLH) transcription factor required for OPC de-
velopment and maintained at all stages of oligodendrocyte
development (17, 21, 29, 36, 43). In contrast to the defect
observed for NG2 and Pdgfra OPCs, analysis of Olig2 ex-
pression revealed identical numbers of parenchymal Olig2
cells in CK2 telencephalons and wild-type controls at E14.5
and E16.5 (Fig. 4A). However, by E18.5, a small decrease
(30%) in the number of parenchymal Olig2 cells was ob-
served in CK2 telencephalons. Because (i) Olig2 identifies
both neural progenitors and OPCs (27, 28) and (ii) the de-
crease in the number of parenchymal Olig2 cells is lower than
the decrease in the number of Pdgfra OPCs in CK2 brains
(0% versus 75% at E16.5 and 30% versus 90% at E18.5),
parenchymal Olig2 cells in CK2 brains may represent
stalled neural progenitors unable to progress along the oligo-
dendrocyte lineage. Alternatively, these Olig2 cells may rep-
resent abnormal glia. To investigate whether the decrease in
OPC numbers was due to defective proliferation of parenchy-
mal Olig2 progenitors as described for NSCs (Fig. 2B), we
determined the ratio of Ki67 Olig2 cells to total Olig2 cells
in the parenchyma of wild-type and CK2 telencephalons at
E16.5 and E18.5 (Fig. 4B). Proliferation of parenchymal
Olig2 cells was unchanged in CK2 brains and is therefore
unlikely to account for OPC deficiency. Because parenchymal
Olig2 progenitors originate from Olig2 neuroepithelial cells
in the VZ (28, 29), the decrease in the number of Olig2 cells
in the parenchyma of CK2 brains may be a consequence of
a defective proliferation of Olig2 cells in the VZ (Fig. 4C).
The discrepancy observed between the effects of CK2 disrup-
tion on the proliferation of NSCs in the VZ and that of Olig2
FIG. 5. CK2 regulates NSC proliferation in neurosphere cultures.
Primary neurospheres (N1; 4DIV and 7DIV) derived from E18.5 fore-
brain NSCs are shown. Compared to wild-type controls, CK2loxP/loxP,
Nestin-cre primary neurospheres in 7DIV cultures became smaller and
did not generate secondary neurospheres (N2) after dissociation
(7DIV). The ratio (percentage) of generated primary neurospheres to
E18.5 forebrain-dissociated cells (6 primary neurosphere cultures per
genotype) in CK2loxP/loxP, Nestin-cre 4DIV cultures was not different
from that of wild-type controls. The number of cells obtained from
dissociated CK2loxP/loxP, Nestin-cre primary neurospheres in 7DIV
cultures was significantly reduced compared to that from wild-type
controls (***, P 
 4.3  10
7 [3 primary neurosphere cultures per
genotype]). Scale bar, 100 m.
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progenitors in the parenchyma may reflect different mechanisms
involved in the control of the proliferation of progenitors down-
stream of the stem compartment. Collectively, these data sug-
gest that CK2 loss leads to a defect in OPC specification of
Olig2 progenitors during telencephalon development (Fig. 4C).
CK2 is required for neural stem cell proliferation and
oligodendroglial differentiation in neurosphere culture. Em-
bryonic NSCs located in the telencephalic VZ have been iden-
tified by their ability in vitro to generate neurospheres in re-
sponse to FGF2 and EGF stimulation (38). In the absence of
growth factors, neurosphere cells differentiate into neurons,
astrocytes, and oligodendrocytes. To confirm whether CK2
loss affects NSC maintenance as shown in vivo, we cultured
neurospheres derived from CK2 E18.5 forebrains and in-
duced their differentiation. There was no significant difference
in the numbers of primary neurospheres generated from E18.5
wild-type and CK2 forebrains in response to FGF2-EGF after
4 days of in vitro culture (4DIV) (Fig. 5). As observed in 7DIV
cultures, wild-type cells formed large neurospheres, whereas
CK2 neurospheres did not expand. This was reflected by a
significant reduction (95%) in the number of cells obtained
from dissociated CK2 neurospheres. In addition, we were
unable to generate CK2 secondary neurospheres, suggesting
that the self-renewing potency of CK2 NSCs was severely
compromised. After differentiation, CK2 neurosphere cells
formed -tubulin III-positive neurons and GFAP astrocytes
but failed to generate O4 differentiating OPCs (Fig. 6A). To
confirm whether this defect was the result of a failure of OPC
specification as observed in vivo, we examined NG2 and Pdgfra
expression in differentiated neurosphere cultures. In striking
contrast to control cultures, CK2 neurospheres did not gen-
erate any NG2 or Pdgfra OPCs (Fig. 6B). To further ad-
dress the requirement of CK2 in NSC proliferation and in
oligodendrogenesis, we expressed an HA-tagged CK2 protein
in CK2/ NSC-derived embryonic stem (ES) cells (Fig. 7)
(2). Such CK2/ NSCs expressing HA-CK2 were able to
proliferate and to generate O4 differentiating OPCs, exclud-
ing a genetic side effect associated with targeting of the CK2
locus. Taken together, these results suggest that the cell-au-
tonomous defect(s) caused by CK2 disruption results in de-
ficient NSC proliferation and OPC specification.
Olig2 is an interacting partner of CK2 subunit and a strict
CK2-dependent substrate in vitro. Given the essential roles
of Olig2 and CK2 for OPC specification in fetal and late
embryonic development (17, 21, 36, 43; this study) and the
regulation of the oligodendroglial activity of Olig2 by phosphor-
ylation (31), we investigated whether Olig2 may be a potential
CK2 substrate. Amino acid sequence analysis of mouse Olig2
revealed that most putative CK2 phosphorylation sites (S/T;
E/D/S n  1, n  1, n  2, and/or n  3) are present within an
FIG. 6. CK2 disruption impairs OPC specification in neurosphere cultures. (A) Primary neurospheres derived from E18.5 forebrains were
tested for their multipotency after differentiation. Cells were immunolabeled with the neuronal marker Tuj1 (green), the astrocytic marker GFAP
(green), and the oligodendroglial marker O4 (red). The ratio (percentage) of cells expressing lineage-specific markers to the total cell number
evaluated by Hoechst-stained nuclei (blue) showed an absence of O4 cells (***, P 
 1.3  10
8 [12 neurosphere cultures per genotype])
concomitant with a significant increase of GFAP astrocytes (***, P 
 2.9  10
4) in CK2loxP/loxP, Nestin-cre cultures compared to the number
in wild-type controls. The percentages of Tuj1 neurons did not differ between wild-type and mutant cultures. (B) CK2 loss altered the
specification of NG2 (green) and Pdgfra (red) OPCs in differentiation cultures. Scale bars, 100 m.
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N-terminal fragment encompassing M1 to Y177. We designed a
GST-Olig2(1-177) fusion protein that includes mouse Olig2
amino acids 1 to 177 (Fig. 8A) and determined the CK2-
dependent incorporation of [	-32P]ATP into the purified frag-
ment. As shown in Fig. 8B, the Olig2(1-177) fragment was
directly phosphorylated by CK2 only in the presence of the
regulatory subunit CK2. We further investigated CK2-de-
pendent phosphorylation of Olig2 by analyzing CK2 and Olig2
phosphorylation activities in fractions obtained after ion-ex-
change chromatography of wild-type E18.5 forebrain extracts
(Fig. 8C). Phosphorylation experiments and Western blot anal-
ysis revealed coelution of CK2 and Olig2-dependent kinase.
This coelution occurred in fractions containing the highest
CK2/CK2 subunits ratio. Moreover, no coelution of CK2
and Olig2-dependent kinase was observed when the chroma-
tography was performed with CK2 forebrain extracts (data
not shown). In addition, Olig2 phosphorylation was abolished
in the presence of 10 M TBB, a specific in vitro CK2 inhibitor
(data not shown). Taken together, these results suggest that
the CK2 tetrameric holoenzyme (22) is an Olig2 kinase.
To delineate which particular motif of the mouse Olig2(1-
177) fragment was involved in the phosphorylation by the CK2
holoenzyme, we performed two-dimensional tryptic phos-
phopeptide mapping (Fig. 8D). Analysis of the maps of 32P-
labeled phosphopeptides revealed multiple spots. A major spot
was suitable for Edman degradation. The released detectable
radioactivity was observed mainly after cycles 9 and 11. Only
one Olig2(1-177) tryptic peptide had serine/threonine residues
at positions 9 and 11, allowing the identification of major
phosphorylated sites at Ser85 and Ser87 in a serine-threonine-
rich domain (STR77-94, tryptic peptide 77SSSSSTSSSTSSAAT
SSTK95) highly conserved in the human sequence. It should be
noted that minor phosphorylation sites were also detected at
Ser84, Thr86, and Ser88. Thus, these results identify the Olig2
STR sequence as an unconventional major domain of multiple
acceptors for phosphorylation by the CK2 holoenzyme.
To investigate the regulation of Olig2 phosphorylation by
CK2, we tested the capacity of CK2 to interact with Olig2.
GST pull-down assays showed that CK2 interacts with the
bHLH fragment of Olig2 [Olig2(109-177)] but fails to interact
with the fragment containing the STR domain [Olig2(1-108)]
(Fig. 8E). Surprisingly, this Olig2(1-108) fragment was not
phosphorylated by the CK2 holoenzyme (data not shown).
Preincubation of CK2 with CK2 subunits which generate
the tetrameric holoenzyme did not prevent its interaction with
the bHLH Olig2(109-177) fragment (data not shown). We
confirmed that CK2 can interact with Olig2 by coimmuno-
precipitation of Flag-tagged CK2 with HA-tagged full-length
FIG. 7. Exogenous CK2 expression in NSC-derived CK2/ embryonic stem (ES) cells promotes proliferation and oligodendroglial differ-
entiation. (A) Clonal selection of CK2/, Cre–pMSCV-puro-cultured (Cre/puroR) ES cells expressing exogenous HA-CK2wt/Neor protein.
CK2/wt, Cre/puroR ES cell clones were generated in parallel and served as positive controls. (B) Western blot analysis with anti-CK2 (left panel)
and anti-HA (right panel) antibodies of CK2loxP/ ES cells, CK2loxP/ and HA-CK2wt/Neor ES cells, and CK2/, Cre/puroR, and HA-
CK2wt/Neor ES cells. Note the complete absence of the endogenous CK2 protein in the CK2/ ES cell extract. (C) Proliferation analysis of
NSC-derived ES cells. The ratio (percentage) of the number of cells present in neurosphere-derived CK2/ ES cells expressing the exogenous
HA-CK2wt protein to the number of cells present in control neurosphere-derived CK2/wt ES cells was unchanged when normalized to the
CK2/wt ES cell line (7 differentiation cultures). (D) O4 differentiating OPCs were identified from neurosphere-derived CK2/ ES cells
expressing the exogenous HA-CK2wt protein and allowed to differentiate. Scale bar, 100 m.
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FIG. 8. CK2 positively modulates CK2-dependent phosphorylation of the Olig2(1-177) fragment in vitro. (A) Primary structure of mouse
Olig2 and schematic representation of the Olig2 fragments used in this study. Represented are the serine-threonine-rich domain sequence (STR,
amino acids 77 to 94), and the basic helix-loop-helix sequence (bHLH, amino acids 109 to 164). (B) Autoradiography of the purified recombinant
GST-Olig2(1-177) fusion fragment after in vitro phosphorylation by the CK2 catalytic subunit () alone or in combination with increasing amounts
of the CK2 regulatory subunit (), which generate increased amounts of the holoenzyme (22). Note that CK2, an autosubstrate of the catalytic
 subunit, competed in the reaction for the CK2 phosphorylation of Olig2 when present in excess. Protein normalization was controlled by
Coomassie blue staining (*). (C) DEAE-Sephacel chromatography of crude wild-type E18.5 forebrain protein extracts. Each fraction was analyzed
for consensus relative CK2 activity with the RRREDEESDDEE synthetic substrate/peptide and for relative CK2-dependent Olig2(1-177) kinase
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mouse Olig2(1-323) after transient expression in Cos7 cells
(Fig. 8F). Together, these data suggest that the bHLH domain
of Olig2 is a docking site to promote the recruitment of CK2
via physical interaction with its regulatory CK2 subunit for
efficient Olig2 phosphorylation on its STR sequence (Fig. 8G).
The CK2-targeted STR domain is required for the oligoden-
droglial activity of Olig2 in neurosphere culture. We next
asked whether the CK2-phosphorylated STR domain is in-
volved in mediating Olig2 biological function. Because of the
many serine and threonine acceptor residues in the Olig2 STR
that could potentially compensate for inactivation of the Ser85
and Ser87 major phosphorylation sites, we generated an Olig2
deletion mutant that lacks the entire STR77-94 domain (HA-
Olig2STR). Transient transfection into Cos7 cells demon-
strated identical levels of expression of HA-Olig2wt (amino
acids 1 to 323; full-length) and HA-Olig2STR proteins (Fig.
9A). We infected Olig2/ neurosphere cultures (18) with ret-
roviruses encoding HA-Olig2wt or HA-Olig2STR and tested
their potential to differentiate into the oligodendroglial lineage
(Fig. 9B). As expected, expression of HA-Olig2wt in Olig2/
NSCs restored the production of O4 differentiating OPCs. In
contrast, Olig2/ NSCs transduced with HA-Olig2STR sig-
nificantly failed to differentiate into O4 cells. These findings
demonstrate that, in vitro, the CK2-targeted STR domain is
required for the oligodendroglial function of Olig2.
DISCUSSION
Kinase-dependent pathways regulating NSC maintenance
and fate specification are largely unknown. Here, we inacti-
vated the protein kinase CK2 regulatory subunit (CK2) gene
in CNS embryonic neural progenitors and showed that CK2
is an important modulator of telencephalon development.
Conditional CK2 mutant mice display impaired NSC prolif-
eration, as well as defective OPC specification. We show that
CK2 interacts physically with the bHLH transcription factor
Olig2, an essential regulator of oligodendroglial differentia-
tion, thereby allowing its serine-threonine-rich (STR) domain
to be phosphorylated by CK2. Finally, we show that the Olig2
STR domain mediates the oligodendroglial activity of Olig2.
Our results suggest that CK2 could mediate OPC specifica-
tion through the modulation of the oligodendroglial activity of
Olig2.
We present the first report of an in vivo role for CK2 in
NSC proliferation in mammals. Loss of CK2 results in re-
duced numbers of dividing cells in the embryonic germinal
zone, and our in vitro neurosphere assays show that CK2 is
required for NSC proliferation and self-renewal. The altered
nuclear morphology of BrdU CK2 NSCs in the ventricular
zone (Fig. 2B) is reminiscent of a cell cycle arrest event and
suggests an interkinetic nuclear migration defect (40). During
G1, the nuclei of NSCs ascend to the basal side of the VZ,
where S phase is completed. Nuclei descend back toward the
ventricular surface during G2, and this is where they stay dur-
ing mitosis. The present study suggests that CK2 may control
this process in the neural stem compartment, leading to a block
in the G1/S phase in CK2
 NSCs. Therefore, CK2 NSCs
would not proceed through the G2 phase. Consequently, it
would explain the near absence of PH3-positive mitotic CK2
NSCs in the VZ (Fig. 2B) and the normal proliferation of the
more downstream population of Olig2 parenchymal progen-
itors in CK2 embryos (Fig. 4B). Recently, it has been dem-
onstrated that nuclear migration is governed by centrosomal
specific microtubule-regulating proteins (40) and reported that
CK2 is required for centrosomal normality (1). However, a
strict CK2-dependent CK2 substrate(s) involved in NSC pro-
liferation has not been described.
We also show that CK2 NSCs are specifically devoid of
oligodendroglial potency. Our in vivo and in vitro studies dem-
onstrate that depletion of the CK2 gene in embryonic neural
progenitors blocks the production of NG2 and Pdgfra
OPCs. Several observations are in favor of a cell-intrinsic reg-
ulation by CK2 in OPC specification per se. (i) In E16.5
CK2 telencephalons, the number of parenchymal Olig2
progenitors was normal, despite a strong defect in NG2 and
Pdgfra OPCs, and by E18.5, whereas the number of Olig2
progenitors increased, the number of OPCs in CK2 telen-
cephalons remained low compared to that in wild-type controls
(Fig. 3 and 4). (ii) Olig2 cell proliferation was unchanged in
CK2 brains (Fig. 4B). (iii) CK2 neurosphere cultures
recapitulated the deficiency in OPC specification observed in
vivo (Fig. 6). (iv) CK2 neurospheres cultured in the pres-
ence of other factors (PDGF-AA and insulin-like growth fac-
tor I [IGF-I]) were unable to differentiate into oligodendro-
cytes (data not shown), suggesting that a defect in a particular
extracellular instruction for NSC specification to oligodendro-
genesis cannot account for OPC deficiency (3, 5, 8, 14, 35). (v)
CK2 is required to promote oligodendrogenesis in NSC-de-
rived embryonic stem (ES) cells (Fig. 7). Thus, CK2-depen-
dent specification of OPCs may correspond to a molecular
mechanism(s) shared by the multiple independent molecular,
regional, and temporal origins of progenitors in the forebrain
(reviewed in reference 28) and controlled by CK2.
Genetic studies in mice demonstrated that during fetal and
late embryogenesis, the bHLH transcription factor Olig2 is
necessary for specification of progenitors into OPCs/oligoden-
activity. Activity profiles were normalized to the activity detected in the peak fractions. In parallel, a sample of each fraction was immunoblotted
to detect the presence of CK2 and CK2 proteins (lower panels). (D) Two-dimensional (2D) phosphopeptide mapping analysis of CK2-
dependent Olig2(1-177) phosphorylation. The major phosphopeptide (arrowhead; upper panel) was subjected to automated Edman degradation
and released derivates from each cycle were spotted onto plates and autoradiographed (lower panel). Deduced amino acids in the Olig2 sequence
are indicated above or below the spots. (E) Recombinant GST fusion proteins containing different Olig2 fragments (1 to 177, 1 to 108, and 109
to 177) were incubated with [35S]methionine-labeled CK2. The ability of the GST fusion proteins to pull down the CK2 subunit was detected
by autoradiography after electrophoresis. On the left, one-tenth of the input is shown. Loading controls were checked after Coomassie blue staining
of the gel (*). (F) Coimmunoprecipitation of Flag-CK2 and HA-Olig2(1-323) in Cos7 cells. Flag-CK2 was immunoprecipitated (IP) with
anti-Flag antibody, and the immunoprecipitated complexes were analyzed by Western blotting (WB) with anti-HA and anti-CK2 antibodies. Hc,
heavy chain; Lc, light chain. (G) Schematic representation of the suggested CK2-Olig2 interaction.
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drocytes (17, 21, 36, 43). Multiple regulations such as interac-
tions (NFIA/B, SCL, and ID4) and phosphorylation (Akt/pro-
tein kinase B [PKB]) that inhibit Olig2 function dictate a loss
into the oligodendroglial lineage (6, 24, 30, 31). The increase in
astrocytogenesis observed in CK2 neurosphere cultures af-
ter differentiation (Fig. 6A) is compatible with a glial switch
following loss of the oligodendroglial function of Olig2 (6, 7,
21, 24, 30, 31, 36, 43). However, whether CK2 modulation of
astrocytic instruction is direct or a consequence of a regulation
of oligodendrocyte differentiation is unclear. We show that the
Olig2(1-177) fragment is a strict CK2-dependent CK2 sub-
strate, probably through a CK2-specific Olig2 recruitment by
direct interaction with the bHLH domain, and that CK2 is an
Olig2 kinase in forebrain extracts (Fig. 8). CK2-dependent
major phosphorylation occurs in the STR domain. In neuro-
sphere assays, we demonstrated that the CK2-targeted STR
domain is required for the full oligodendroglial function of
Olig2 (Fig. 9). Although we cannot exclude phosphorylation(s)
of the STR domain by one or more other serine/threonine
kinases, our results do not definitively prove, but do suggest,
that CK2-dependent CK2 activity may play a role as a deter-
minant in the combinatorial code that trigger Olig2-dependent
oligodendrocyte lineage progression. Alternatively, we cannot
rule out other CK2-dependent transcription factor substrates
important for the oligodendroglial network which could act in
synergy inside the same genetic pathway.
During CNS development, Olig2 is sequentially required for
the generation of subsets of motor neurons (E9 to E10.5) and
OPCs (E12.5 to E14.5) (21, 36, 43). If the assumption for a
defect in Olig2 function in CK2 progenitors is correct, then
it is intriguing that the process of neurogenesis is not affected.
However, in CK2 mutant brains, complete ablation of CK2
does not occur before E18.5, by which neurogenesis is largely
completed. Additional studies will be needed to address the
earlier role of CK2 in neuronal development.
The essential role of CK2 for cell viability initially detected
in ES cells (2) precluded analysis of later roles for CK2 during
development. Our conditional strategy revealed unexpected
roles for CK2 in the CNS. We demonstrated that CK2
represents a unique signaling component in NSC proliferation
and self-renewal and in the oligodendroglial lineage-restricted
pathway. If CK2-dependent CK2 activity is required for can-
cer stem cell proliferation and self-renewal as it is for NSCs,
then inhibitors of interaction between the CK2 regulatory
subunit and CK2 catalytic subunits ( and ) could be useful
chemotherapeutic agents. Conversely, because differentiation
block of OPCs has been demonstrated to cause neurodegen-
erative diseases, such as chronic multiple sclerosis (16), acti-
vation of CK2-dependent CK2 activity may be useful in pro-
moting remyelination.
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FIG. 9. The Olig2 STR domain is required for NSC oligodendro-
glial potency in neurosphere cultures. (A) Transient expression anal-
ysis of the Olig2STR mutant protein in Cos7 cells. Comparative
pattern expressions of full-length (mouse; amino acids 1 to 323) HA-
Olig2wt and HA-Olig2STR in transiently transfected Cos7 cells. An-
ti-HA Western blots revealed shifted-up bands within the HA-Olig2wt-
transfected protein extracts (arrowheads), and these were not detected
in the HA-Olig2STR version. This observation is reminiscent of the
STR sequence as phosphorylated sites. “MOCK” indicates a control
experiment performed with the empty vector. Amounts of protein are
as follows: 1, 4 g; 2, 8 g; 3, 16 g. (B) Olig2/ NSCs were trans-
duced with HA-Olig2wt(1-323) and HA-Olig2STR. NSC-derived neu-
rospheres were allowed to differentiate and stained with HA (green) to
detect exogenous Olig2 and with O4 (red) to assess for oligodendro-
glial potency. Olig2/ and Olig2/ assays are shown in parallel. The
ratio (percentage) of cells expressing the O4 oligodendroglial marker
to the total cell number evaluated by Hoechst-stained nuclei (blue)
showed a significant deficiency (***, P 
 5.6  10
7 [4 neurosphere
cultures per genotype]) in the oligodendroglial activity of the HA-
Olig2STR mutant compared to that of the HA-Olig2wt control. Scale
bars, 50 m.
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help with radiochemical sequencing, and I. Yakymovych for his com-
petence in phosphopeptides analysis.
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